KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Leases: 2023-2024

Historic Capital Leases for Aurinia Pharmaceuticals (AUPH) over the last 2 years, with Dec 2024 value amounting to $58.6 million.

  • Aurinia Pharmaceuticals' Capital Leases fell 15.51% to $55.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 15.51%. This contributed to the annual value of $58.6 million for FY2024, which is 22.42% down from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' Capital Leases is $58.6 million, which was down 22.42% from $75.5 million recorded in FY2023.
  • Aurinia Pharmaceuticals' Capital Leases' 5-year high stood at $75.5 million during FY2023, with a 5-year trough of $58.6 million in FY2024.
  • Over the past 2 years, Aurinia Pharmaceuticals' median Capital Leases value was $67.0 million (recorded in 2023), while the average stood at $67.0 million.
  • Data for Aurinia Pharmaceuticals' Capital Leases shows a maximum YoY declined of 22.42% (in 2024) over the last 5 years.
  • Over the past 2 years, Aurinia Pharmaceuticals' Capital Leases (Yearly) stood at $75.5 million in 2023, then dropped by 22.42% to $58.6 million in 2024.